–Up to 68.2% mean relative reduction in liver fat content from baseline among biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients receiving…
SHANGHAI and HEIDELBERG, Germany, June 10, 2024 /PRNewswire/ — Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, released preclinical data…